

Flow restoration in below the knee arteries

Peripheral thrombectomy in a 3F crossing profile

ANGIOJET SOLENT® dista

Solent® Family of AngioJet® Thrombectomy Catheters

The newest member of our Solent Family, offering our longest and smallest diameter catheter for accessing and treating arterial vessels > 1.5mm, below the knee and in upper extremities via radial access.

Solent Dista – High Thrombus Removal Power in our Longest Length and Smallest Diameter

High-speed saline jets inside the Solent catheter create a powerful low pressure zone that pulls thrombus into the catheter and removes it from the body. Cross-Stream® catheter technology can treat larger arteries with minimal vessel wall contact. The Solent Dista catheter is compatible with the Ultra Thrombectomy System, 4FR sheath, and 0.014 guidewires—a treatment device that works with the standards of your practice.

Improved Site Access

- New nitinol 3F distal section allowing access to smaller, tortuous vasculature
- Braided shaft design offering pushability to access lesions
- Distal shaft with hydrophilic coating to reduce drag and ensure smooth delivery

Power Pulse® Delivery is now in our smallest catheter



Solent Dista is Power Pulse enabled for difficult-to-remove thrombus. Power Pulse Delivery enables infusion of physician-specified fluids, including thrombolytic agents, directly into the clot, saturating the thrombus. The action of Power Pulse Delivery helps disrupt difficult thrombus and prepare it for rapid removal using the Solent Dista catheter. The result is a rapid and effective means for removing thrombus from peripheral arteries.[1]



Mechanism of Action
Cross-Stream® technology utilizes complex fluid flow patterns to capture and remove thrombus.

Catheter Specifications

System Compatibility	AngioJet Ultra
Vessel Diameter	≥ 1.5mm
Working Length	145cm
Shaft Diameter	4F (130cm) / 3F (15cm)
Double Marker Band	15 mm
Guidewire Compatibility	OTW 0.014"
Sheath Compatibility	4F

Order Information

AngioJet Solent Dista Thrombectomy Set	
Part number	111303-TAB

For use only with the AngioJet Ultra System

1 Shammas NW, Dippel EJ, et al. Dethrombosis of the lower extremity arteries using the power-pulse spray technique in patients with recent onset thrombotic occlusions: results of the DETHROMBOSIS registry. J Endovascular Therapy. 2008; 15:570-579.

Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific *Information for Use* for your country.

AngioJet® Thrombectomy Systems for Peripheral Use

Indications/Contraindications
AngioJet and AngioJet Ultra Systems are indicated for breaking up and removing thrombus from infra-inguinal peripheral arteries, upper and lower extremity peripheral arteries, upper extremity peripheral veins, ileofemoral and lower extremity veins, A-V access conduits, and for use with the AngioJet Ultra Power Pulse Kit for the control and selective infusion of physician specified fluids, including thrombolytic agents, into the peripheral vascular system. Do not use in patients: who are contraindicated for endovascular procedures, who cannot tolerate contrast media, and in whom the lesion cannot be accessed with the wire guide.

Warnings and Precautions
The system has not been evaluated for treatment of pulmonary embolism or for use in the carotid or cerebral vasculature. Some AngioJet devices have not been evaluated for use in coronary vasculature. Operation of the catheter may cause embolization of some thrombus and/or thrombotic particulate debris. Cardiac arrhythmias may occur and cardiac rhythm should be monitored during catheter use and appropriate management employed, if needed. Systemic heparinization is advisable to avoid pericatheterization thrombus and acute rethrombosis. Operation of the system causes transient hemolysis. Large thrombus burdens may result in significant hemoglobinemia which should be monitored. Consider hydration, as appropriate.

Potential Adverse Events
Potential adverse events (in alphabetical order) which may be associated with use of the system include, but are not limited to, the following: abrupt closure of treated vessel, acute myocardial infarction, acute renal failure, bleeding from access site, cerebrovascular accident, death, dissection, embolization (proximal or distal), hematoma, hemolysis, hemorrhage requiring transfusion, hypotension/hypertension, infection at access site, pain, pancreatitis, perforation, pseudoaneurysm, reactions to contrast medium, thrombosis/occlusion, total occlusion of treated vessel, vascular aneurysm, vascular spasm, and vessel wall or valve damage.

Refer to product labeling for device-specific indications, contraindications, warnings/precautions, and adverse events. Rx only. PER – October 2010

CE 0086

4041-014 02-13

G.RI.02.2013.0034

Bayer HealthCare

Manufacturer:
MEDRAD, INC.
One Medrad Drive
Indianola, PA 15051-0780 USA
Ph: +1 (412) 767-2400
Other: +1 (800) 633-7231
Fax: +1 (412) 767-4120
www.medrad.com

European Authorized Representative:
MEDRAD Europe B.V.
P.O. Box 205
6190 AE Beek
The Netherlands
Ph: +31 (0) 43-3585600